GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » EV-to-EBITDA

SWOBY (Swedish Orphan Biovitrum AB) EV-to-EBITDA : 12.51 (As of Dec. 12, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Swedish Orphan Biovitrum AB's enterprise value is $11,218 Mil. Swedish Orphan Biovitrum AB's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $897 Mil. Therefore, Swedish Orphan Biovitrum AB's EV-to-EBITDA for today is 12.51.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's EV-to-EBITDA or its related term are showing as below:

SWOBY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.27   Med: 14.46   Max: 1219.3
Current: 13.57

During the past 13 years, the highest EV-to-EBITDA of Swedish Orphan Biovitrum AB was 1219.30. The lowest was 8.27. And the median was 14.46.

SWOBY's EV-to-EBITDA is ranked better than
52.65% of 718 companies
in the Drug Manufacturers industry
Industry Median: 14.19 vs SWOBY: 13.57

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-12), Swedish Orphan Biovitrum AB's stock price is $14.025. Swedish Orphan Biovitrum AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $0.495. Therefore, Swedish Orphan Biovitrum AB's PE Ratio (TTM) for today is 28.33.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Swedish Orphan Biovitrum AB EV-to-EBITDA Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB EV-to-EBITDA Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.09 9.43 11.27 11.83 15.25

Swedish Orphan Biovitrum AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.71 15.25 15.00 14.59 14.00

Competitive Comparison of Swedish Orphan Biovitrum AB's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's EV-to-EBITDA falls into.



Swedish Orphan Biovitrum AB EV-to-EBITDA Calculation

Swedish Orphan Biovitrum AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=11217.912/896.514
=12.51

Swedish Orphan Biovitrum AB's current Enterprise Value is $11,218 Mil.
Swedish Orphan Biovitrum AB's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $897 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Swedish Orphan Biovitrum AB  (OTCPK:SWOBY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Swedish Orphan Biovitrum AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=14.025/0.495
=28.33

Swedish Orphan Biovitrum AB's share price for today is $14.025.
Swedish Orphan Biovitrum AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.495.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Swedish Orphan Biovitrum AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).